Pathogen-associated heterogeneity in pulmonary sepsis: from inflammatory phenotypes and transcriptomic endotypes to precision medicine
- 1Department of Emergency Intensive Care Unit, Second Affiliated Hospital of Kunming Medical University
- 2Department of Gastrointestinal Surgery, First Affiliated Hospital of Kunming Medical University
- 3Department of Emergency, Second Affiliated Hospital of Kunming Medical University
Abstract
Sepsis is a heterogeneous syndrome, and pulmonary infection is its commonest source. Pulmonary sepsis carries a particularly high mortality, especially in patients who develop refractory septic shock, yet it is still managed as a single disease. Conventional diagnostic criteria, based on organ dysfunction, describe the consequences of the host response rather than its biological diversity, and this mismatch helps to explain why immunomodulatory trials have repeatedly failed in unselected patients. In this review we summarise how pathogen characteristics interact with the alveolar immune microenvironment to produce distinct host-response phenotypes, and how those phenotypes are captured by clinical classifiers, plasma protein biomarkers and blood transcriptomic endotypes — among them SRS1/2, Mars1–4, SENECA and USE-1/2. Three problems currently limit translation. The classification systems overlap only in part, and should not be used interchangeably. Endotypes change over time, so a single measurement at baseline can misclassify a patient. And most of the evidence linking particular pathogens to particular phenotypes is associative, and comes from ARDS, general sepsis, severe pneumonia or COVID-19 cohorts rather than from pulmonary sepsis itself. We then review the phenotype-dependent responses to fluid strategy, corticosteroids, statins, endotoxin removal, cytokine-directed therapy and checkpoint inhibition, and consider why several biomarker-guided trials produced pharmacodynamic signals without clinical benefit. Pathogen-informed, repeatedly measured host-response phenotypes, tested in adaptive trials with enrichment, offer the most realistic route to precision immunotherapy in pulmonary sepsis.
Related
- Township-level spatial heterogeneity and associated factors of diagnostic delay among pulmonary tuberculosis patients in Central China
- Identification of candidate selenium-associated transcriptomic biomarkers in chronic obstructive pulmonary disease: an integrated bioinformatics and expression validation study
- Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures
- Integrated transcriptomic and single-cell analyses define neuronal heterogeneity and PDIA4-associated malignancy in glioblastoma
- MHC-II+ G-MDSC expressing CD80, CD86, or ICOSL are associated with pro-inflammatory CD4+ T cells phenotypes in the lungs of lupus-prone mice
BibTeX
@article{wang2026pathogenassociated,
title = {{Pathogen-associated heterogeneity in pulmonary sepsis: from inflammatory phenotypes and transcriptomic endotypes to precision medicine}},
author = {Chun Wang and Cheng Xi and Ying Zhang and Ruifang Ma and Mimi Shi and Yu Gao and Liping Liu and Canyu Ning and Anbao Chen},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1973456},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973456/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pathogen-associated heterogeneity in pulmonary sepsis: from inflammatory phenotypes and transcriptomic endotypes to precision medicine
AU - Chun Wang
AU - Cheng Xi
AU - Ying Zhang
AU - Ruifang Ma
AU - Mimi Shi
AU - Yu Gao
AU - Liping Liu
AU - Canyu Ning
AU - Anbao Chen
PY - 2026
DA - 2026/10/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1973456
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973456/full
AB - Sepsis is a heterogeneous syndrome, and pulmonary infection is its commonest source. Pulmonary sepsis carries a particularly high mortality, especially in patients who develop refractory septic shock, yet it is still managed as a single disease. Conventional diagnostic criteria, based on organ dysfunction, describe the consequences of the host response rather than its biological diversity, and this mismatch helps to explain why immunomodulatory trials have repeatedly failed in unselected patients. In this review we summarise how pathogen characteristics interact with the alveolar immune microenvironment to produce distinct host-response phenotypes, and how those phenotypes are captured by clinical classifiers, plasma protein biomarkers and blood transcriptomic endotypes — among them SRS1/2, Mars1–4, SENECA and USE-1/2. Three problems currently limit translation. The classification systems overlap only in part, and should not be used interchangeably. Endotypes change over time, so a single measurement at baseline can misclassify a patient. And most of the evidence linking particular pathogens to particular phenotypes is associative, and comes from ARDS, general sepsis, severe pneumonia or COVID-19 cohorts rather than from pulmonary sepsis itself. We then review the phenotype-dependent responses to fluid strategy, corticosteroids, statins, endotoxin removal, cytokine-directed therapy and checkpoint inhibition, and consider why several biomarker-guided trials produced pharmacodynamic signals without clinical benefit. Pathogen-informed, repeatedly measured host-response phenotypes, tested in adaptive trials with enrichment, offer the most realistic route to precision immunotherapy in pulmonary sepsis.
SN - 1664-3224
ER -